Skip to main content

Table 2 Treatment-related patient characteristics

From: Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium

  Total (%) n = 275 Age <70 years (%) n = 228 Age ≥ 70 years (%) n = 47 p value for group differences
Type of surgery     0.019b
Primary cytoreduction 226 (82.2) 193 (84.6) 30 (70.2)  
Interval debulking 49 (17.8) 35 (15.4) 14 (29.8)  
Surgical interventions     
Adnectomy 259 (94.2) 220 (96.4) 39 (83.0) 0.038b
Hysterectomy 248 (90.2) 212 (93.0) 36 (76.6) 0.006b
Omentectomy 255 (92.7) 212 (93.0) 43 (91.5) 0.720b
Pelvic LAE 191 (69.5) 171 (75.0) 20 (42.6) <0.001b
Paraaortic LAE 184 (66.9) 166 (72.8) 18 (38.3) <0.001b
Appendectomy 110 (40.0) 94 (41.2) 16 (34.0) 0.327b
Splenectomy 22 (8.0) 19 (8.3) 3 (6.4) 1.000b
Large bowel resection 104 (37.8) 87 (38.2) 17 (36.2) 0.798b
Small bowel resection 37 (13.4) 27 (11.8) 10 (21.3) 0.084b
Postop. residual tumor     0.029b
Microscopic 189 (68.7) 163 (71.5) 26 (55.3)  
Macroscopic 86 (31.3) 65 (28.5) 21 (44.7)  
Intraoperative complications     0.532c
Yes 20 (7.2) 16 (7.0) 4 (8.5)  
No 247 (89.9) 209 (91.7) 38 (80.9)  
Unknown 8 (2.91) 3 (1.3) 5 (10.6)  
Postoperative complications     0.495b
Yes 95 (34.6) 82 (36.0) 13 (27.7)  
No 172 (62.6) 143 (62.7) 29 (61.7)  
Unknown 8 (2.9) 3 (1.3) 5 (10.6)  
Mortality rates     
30d-mortality rate 0.0 % 0.0 % 0.0 % 1.000d
60d-mortality rate 1.1 % 0.4 % 2.1 % <0.001d
Chemotherapy     
courses (median, range) 6 (1–8) 6 (1–8) 6 (2–6) 0.156a
Time to chemo after surgery (median, range) 34 (5–188) 34 (5–188) 31.5 (9–127) 0.368a
Treatment concept     0.019b
- Neoadjuvant 49 (17.8) 35 (15.4) 14 (29.8)  
- Adjuvant 226 (82.2) 193 (84.6) 30 (70.2)  
Treatment regimen     <0.001c
- Platinum-based combination 260 (94.5) 223 (97.8) 37 (78.7)  
- Platinum monotherapy 15 (5.5) 5 (2.2) 10 (21.3)  
Response to chemotherapy 205 (74.5) 178 (78.4) 27 (57.4) 0.003b
Optimal oncologic treatment (no residual tumor + combination therapy)     <0.001b
Yes 179 (65.1) 160 (70.1) 19 (40.4)  
No 96 (34.1) 68 (29.8) 28 (59.6)  
Survival (months)     
Median PFS 19 20 12 0.022d
Median OS 48 64 30 <0.001d
  1. Detailed overview of surgical procedures, chemotherapy and prognostic aspects. Parameters were separately analyzed for elderly patients ≥70 years and patients younger than 70 years.
  2. a Man-Whitney-U-test, b Chi2-test, c Fisher’s exact test, d log-rank test.
  3. LAE = lymphadenectomy, PFS = progression free survival, OS = overall survival.